In Addition, Three Senior Executives Will Reinforce the Company’s Drug Development Engine NANTES, France, December 20, 2021–(BUSINESS WIRE)–Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) announces the appointment of Laurence de Schoulepnikoff as Chief Business Officer (CBO), as well as three senior appointments to further strengthen the OSE […]